Sputnik V vaccine
phone-call sandwich
Sputnik V vaccine

Sputnik V vaccine

The first Russian vaccine against COVID-19, developed by the Gamaleya National Center of Epidemiology and Microbiology, registered in August 2020 after the second wave of trials.


Sputnik V vaccine

Sputnik V vaccine

The first Russian vaccine against COVID-19, developed by the Gamaleya National Center of Epidemiology and Microbiology, registered in August 2020 after the second wave of trials. According to its developers, Sputnik-V is more than 95% effective. This vaccine is administered in two doses, at an interval of 21 days. Sputnik-V is a vector vaccine and is effective against all identified strains of the SARS-CoV-2 coronavirus, according to experts. Belarus was the first foreign country to register this Russian drug, followed by authorities in Argentina, Venezuela and several other countries.


Vaccine

Gam-Covid-Vac (trademarked as Sputnik V)

Developer

Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Ministry of Health

Producer

  • Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Ministry of Health

  • BIOCAD (Saint Petersburg)

  • Generium (Vladimir Region)

  • Binnopharm Group (Zelenograd)

Status

Registration certificate issued August 11, 2020.
All four stages of research have been completed: one pre-clinical trial (on animals) and three clinical trials (on people).
Before starting clinical trials, the vaccine passed all preclinical efficacy and safety tests, involving experiments on various types of laboratory animals (including 2 types of primates).

Key information

What’s in the vaccine?

The drug consists of two components, both recombinant adenovirus vectors based on two different forms of the human adenovirus.



Vaccines developed and used in Russia